The controversial news about the coronavirus vaccines continues. Most vaccines have been under the spotlight due to various potential side effects that are pretty severe for some individuals.
It’s been revealed that although it’s very rare, a blood clot syndrome after the very first dose of the Oxford/AstraZeneca vaccine has been reported to carry a high risk of death and can occur in otherwise young and healthy people, according to the latest reports coming from the UK researchers.
In those people aged under 50, blood clots occur in around one in 50,000 people who have received the vaccine, according to the latest data.
Examining symptoms
Researchers examined the symptoms, signs and outcomes in 220 confirmed and probable cases who came to UK hospitals between 22 March and 6 June.
“It’s important to stress that this kind of reaction to the Oxford/AstraZeneca vaccine is very rare,” said Dr Sue Pavord, consultant haematologist at Oxford University Hospitals NHS Foundation Trust and lead author of the analysis published in the New England Journal of Medicine.
More than that, it’s been also revealed that for those who do develop blood clots, the results “can be devastating,” she added as quoted by The Guardian.
“It often affects young, otherwise healthy vaccine recipients and has high mortality. It is particularly dangerous when the patient has a low platelet count and bleeding in the brain.”
“It can affect anybody.”
This was added Beverley Hunt, medical director of Thrombosis UK and professor of thrombosis and haemostasis at King’s College London.
Dr Anthony Fauci drops disturbing news about the pandemic
In other recent news, dr Anthony Fauci dropped some new info about the disease which eventually changed our lives for good.
Fauci released pretty unsettling details about the coronavirus pandemic, managing to disappoint a lot of people who were hoping that we’re on the right track to recovery.
The prestigious expert also addressed these days what will happen with the Covid 19 variants that are able to evade protection.
Stay tuned for more news.
